412 results on '"van Dongen A"'
Search Results
2. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines
3. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
4. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
5. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
6. Differentiation stage of myeloma plasma cells: biological and clinical significance
7. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
8. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
9. Basal Ca2+ signaling is particularly increased in mutated chronic lymphocytic leukemia
10. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
11. Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype
12. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
13. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation
14. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia
15. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation
16. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
17. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer
18. Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats
19. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
20. Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study
21. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK
22. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol
23. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
24. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
25. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment
26. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
27. Genome-wide expression analysis of paired diagnosis–relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype
28. Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27 + IgM + IgD + memory B cells with a distinctive immunophenotype
29. New insights to the MLL recombinome of acute leukemias
30. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
31. Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
32. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis
33. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
34. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
35. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring
36. Childhood secondary ALL after ALL treatment
37. Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy
38. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The ‘big sister’ of the infant disease?
39. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement
40. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
41. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting
42. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936
43. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936
44. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936
45. Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes
46. Identification of Notch target genes in uncommitted T-cell progenitors: no direct induction of a T-cell specific gene program
47. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks
48. Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia
49. The MLL recombinome of acute leukemias
50. TCRγδ+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRγδ+ T-cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.